EUVIMEDEUVIMED entdecken
Crossref

Contraindications to tissue plasminogen activator thrombolysis for acute lower extremity ischemia

Nikita Singh, Tyler Santos iD, Ali Basil Ali, Hason Khan, Pavel Kibrik iD, Jason Storch, Halbert Bai, Mark Awad iD, Ronak Patel, Michael Huber, Enrico Ascher, Natalie Marks und 1 weitere

Vascular · 2025

DOI: 10.1177/17085381241273211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vascular, 2025. Verfasst von Nikita Singh und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Arkansas for Medical Sciences, Little Rock, AR, USA. Hauptthemen laut MEDLINE: Ischemia, Fibrinolytic Agents, Thrombolytic Therapy, Tissue Plasminogen Activator. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Previous randomized prospective trials have demonstrated the effectiveness of transcatheter tissue plasminogen activator (tPA) thrombolysis in treating acute limb ischemia (ALI) compared to conventional surgery. These pivotal trials have also highlighted contraindications for these procedures. Given recent advancements in techniques and technology, our aim is to reassess the relevance of these contraindications in contemporary practice.

Methods

A retrospective chart analysis was performed utilizing the inpatient medical records of consecutive individuals who underwent tPA treatment for acute limb ischemia (ALI) from September 2016 to April 2022. Inclusion criteria encompassed patients aged 18 and above displaying clinical symptoms and imaging evidence of ALI within 14 days. All patients received tPA with suction thrombectomy following the fast-track thrombolysis protocol. In cases where a persistent thrombus or stenosis was detected, catheter-directed thrombolysis was considered overnight, and patients underwent angiography and reassessment in the operating room subsequently.

Results

Patients were classified into two groups based on the STILE trial’s established contraindications for endovascular treatment in acute limb ischemia (ALI). If a patient had any of these contraindications, they were placed in the contraindicated group. This resulted in 24 patients (32%) in the contraindicated group and 52 patients (68%) in the non-contraindicated group. No statistically significant demographic variations were observed between these groups. Contraindications in our study included uncontrolled hypertension (12/24, 50%), recent invasive procedures (7/27, 29%), history of cerebrovascular accident (CVA) within 6 months (3/24, 12%), and intracranial malformation/neoplasms (2/24, 8%). Three patients within the non-contraindicated group experienced bleeding complications: two with puncture site bleeds and one with nasal bleeding. In contrast, one patient in the contraindicated group had transient postoperative hematuria. There were no significant differences in bleeding complications observed between the two groups ( p = .771). Additionally, no amputations were observed within our population.

Conclusions

In light of our study results and advancements in endovascular therapies, we can now safely and efficiently treat patients who were previously considered contraindicated for such treatments. It is essential to individualize treatments and carefully balance the risks and benefits of endovascular versus open surgical revascularization for these patients. Additionally, we believe that the nearly 30-year-old guidelines for endovascular therapies need to be revisited and updated to align with modern technology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IschemiaFibrinolytic AgentsThrombolytic TherapyTissue Plasminogen ActivatorLower ExtremityPeripheral Arterial DiseaseHumansRetrospective StudiesMaleFemaleAgedTreatment OutcomeAcute DiseaseMiddle AgedRisk FactorsTime FactorsAged, 80 and overContraindications, DrugRisk AssessmentLimb SalvageThrombectomyContraindications, Procedure

Stichwörter der Autor:innen

Acute limb ischemiacontraindicationsthrombolysistissue plasminogen activator

Substanzen

Fibrinolytic AgentsTissue Plasminogen Activator

Autor:innen und Institutionen

  • University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Total Vascular Care, Brooklyn, NY, USA.
  • St. George's University School of Medicine, St George's, Grenada.
  • Department of Surgery, Hospital of University of Pennsylvania, Philadelphia, PA, USA.
  • Kansas City University, Kansas City, MO, USA.
  • Icahn School of Medicine at Mount Sinai, New York, NY, USA.

ORCID-Profile: Tyler Santos, Pavel Kibrik, Mark Awad

Zitieren

APA

Singh, N., Santos, T., Ali, A. B., Khan, H., Kibrik, P., Storch, J., Bai, H., Awad, M., Patel, R., Huber, M., Ascher, E., Marks, N., & Hingorani, A. (2025). Contraindications to tissue plasminogen activator thrombolysis for acute lower extremity ischemia. Vascular. https://doi.org/10.1177/17085381241273211

Vancouver

Singh N, Santos T, Ali AB, Khan H, Kibrik P, Storch J, et al. Contraindications to tissue plasminogen activator thrombolysis for acute lower extremity ischemia. Vascular. 2025. doi:10.1177/17085381241273211

BibTeX
@article{Singh2025,
  author = {Singh, Nikita and Santos, Tyler and Ali, Ali Basil and Khan, Hason and Kibrik, Pavel and Storch, Jason and Bai, Halbert and Awad, Mark and Patel, Ronak and Huber, Michael and Ascher, Enrico and Marks, Natalie and Hingorani, Anil},
  title = {Contraindications to tissue plasminogen activator thrombolysis for acute lower extremity ischemia},
  journal = {Vascular},
  year = {2025},
  doi = {10.1177/17085381241273211}
}
Kostenlos starten →